YKL-40 in Virus-Associated Liver Disease: A Translational Biomarker Linking Fibrosis, Hepatocarcinogenesis, and Liver Transplantation
Authors:
- Jadranka Pavicic SaricJadranka Pavicic Saric
- Dinka LulicDLDinka Lulic
- Dunja RogicDRDunja Rogic
- Stipislav JadrijevicSJStipislav Jadrijevic
- Danko MikulicDMDanko Mikulic
- Tajana Filipec KanizajTKTajana Filipec Kanizaj
- Nikola PrpicNPNikola Prpic
- Laura Karla BozicLBLaura Karla Bozic
- Ivona AdamovicIAIvona Adamovic
- Iva Bacak KocmanIKIva Bacak Kocman
- Zrinka SarecZSZrinka Sarec
- Gorjana ErcegGEGorjana Erceg
Preprint
- 28 August 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Virus-associated hepatocellular carcinoma (HCC) remains a major global health burden despite effective antiviral therapies. Chronic infection with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) promotes malignant transformation through overlapping pathways of fibrosis, immune dysregulation, and microenvironmental remodeling. YKL-40, a glycoprotein secreted by hepatic stellate cells, hepatocytes under stress, macrophages, and endothelial cells, has emerged as a marker that reflects stromal activation rather than direct hepatocyte injury. Its expression is reinforced by profibrotic and angiogenic circuits, and circulating concentrations correlate with advanced fibrosis, residual risk after viral suppression, and oncologic outcomes. This review synthesizes current evidence on YKL-40 across HBV, HCV, and HDV cohorts, with emphasis on its role in bridging molecular mechanisms to clinical applications. We examine its utility in non-invasive fibrosis assessment, longitudinal monitoring after antiviral therapy, and prognostic modeling in HCC. Particular attention is given to its potential in the liver transplant pathway, where YKL-40 may refine eligibility beyond morphology, inform bridging therapy response, and predict post-transplant recurrence or graft fibrosis. Remaining challenges include its lack of disease specificity, assay variability, and limited multicenter validation. Future integration of YKL-40 into multimarker, algorithm-based frameworks could enable risk-adaptive strategies that align surveillance and transplant decisions with the evolving biology of virus-associated liver disease.Keywords
All Related Versions
This publication has 104 references indexed in Scilit:
- Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfectionHepatology International, 2023
- Single‐cell RNA sequencing reveals the heterogeneity and intercellular communication of hepatic stellate cells and macrophages during liver fibrosisMedcomm, 2023
- HCV Core Protein–ISX Axis Promotes Chronic Liver Disease Progression via Metabolic Remodeling and Immune SuppressionAdvanced Science, 2023
- Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2/EP4 pathwayCellular and Molecular Life Sciences, 2022
- Hepatic fibrosis 2022: Unmet needs and a blueprint for the futureHepatology, 2021
- Liver damage favors the eliminations of HBV integration and clonal hepatocytes in chronic hepatitis BHepatology International, 2021
- Chitinase 3‐like‐1, Tolloid‐like protein 1, and intergenic gene polymorphisms are predictors for hepatocellular carcinoma development after hepatitis C virus eradication by direct‐acting antiviralsIUBMB Life, 2020
- The clinical significance of serum chitinase 3‐like 1 in hepatitis B–related chronic liver diseasesJournal of Clinical Laboratory Analysis, 2020
- Organ system view of the hepatic innate immunity in HCV infectionJournal of Medical Virology, 2016
- Serum Fibrosis Markers Can Predict Rapid Fibrosis Progression After Liver Transplantation for Hepatitis CLiver Transplantation, 2008